246 related articles for article (PubMed ID: 28657431)
1. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
Sasagawa Y; Akai T; Tachibana O; Iizuka H
J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
[TBL] [Abstract][Full Text] [Related]
3. The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.
Mabray MC; Barajas RF; Villanueva-Meyer JE; Zhang CA; Valles FE; Rubenstein JL; Cha S
AJNR Am J Neuroradiol; 2016 Jan; 37(1):74-9. PubMed ID: 26381553
[TBL] [Abstract][Full Text] [Related]
4. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.
Maeyama M; Sasayama T; Tanaka K; Nakamizo S; Tanaka H; Nishihara M; Fujita Y; Sekiguchi K; Kohta M; Mizukawa K; Hirose T; Itoh T; Kohmura E
Cancer Med; 2020 Jun; 9(12):4114-4125. PubMed ID: 32314548
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma.
Shimizu N; Nakao S; Hasunuma H; Nakaseko C; Shimizu T; Ebinuma H; Bujo H
Intern Med; 2024 Mar; ():. PubMed ID: 38432983
[TBL] [Abstract][Full Text] [Related]
6. Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis.
Otto C; Wengert O; Unterwalder N; Meisel C; Ruprecht K
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32393650
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
[TBL] [Abstract][Full Text] [Related]
8. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia.
Lee W; Kim SJ; Lee S; Kim J; Kim M; Lim J; Kim Y; Cho B; Lee EJ; Han K
Ann Clin Lab Sci; 2005; 35(4):407-12. PubMed ID: 16254256
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
[TBL] [Abstract][Full Text] [Related]
10. Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.
Levraut M; Landes C; Mondot L; Cohen M; Bresch S; Brglez V; Seitz-Polski B; Lebrun-Frenay C
Front Immunol; 2022; 13():864133. PubMed ID: 35401550
[TBL] [Abstract][Full Text] [Related]
11. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
Chang CS; Liu HW; Lin SF; Chen TP
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
[TBL] [Abstract][Full Text] [Related]
13. Disease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNS.
Park SJ; Jeong IH; Kong BS; Lee JE; Kim KH; Lee DY; Kim HJ
PLoS One; 2016; 11(11):e0166277. PubMed ID: 27855220
[TBL] [Abstract][Full Text] [Related]
14. Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma.
Kitai R; Sasaki H; Matsuda K; Tsunetoshi K; Yamauchi T; Neishi H; Matsumura K; Tsunoda A; Takeuchi H; Sato K; Kikuta K
Brain Tumor Pathol; 2013 Jan; 30(1):34-9. PubMed ID: 22399193
[TBL] [Abstract][Full Text] [Related]
15. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases.
Iriyama C; Murate K; Iba S; Okamoto A; Goto N; Yamamoto H; Kato T; Mihara K; Miyama T; Hattori K; Kajiya R; Okamoto M; Mizutani Y; Yamada S; Tsukamoto T; Hirose Y; Mutoh T; Watanabe H; Tomita A
Cancer Med; 2023 Aug; 12(16):16972-16984. PubMed ID: 37501501
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL.
Mitobe Y; Matsuda KI; Sonoda Y
Neurol Med Chir (Tokyo); 2023 Mar; 63(3):111-115. PubMed ID: 36682790
[TBL] [Abstract][Full Text] [Related]
17. The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
Hottenrott T; Schorb E; Fritsch K; Dersch R; Berger B; Huzly D; Rauer S; Tebartz van Elst L; Endres D; Stich O
J Neurol; 2018 May; 265(5):1106-1114. PubMed ID: 29511863
[TBL] [Abstract][Full Text] [Related]
18. Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis.
Kimura A; Takemura M; Serrero G; Yoshikura N; Hayashi Y; Saito K; Inuzuka T
J Neurooncol; 2018 May; 137(3):455-462. PubMed ID: 29340960
[TBL] [Abstract][Full Text] [Related]
19. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
20. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
